Differentiated thyroid cancers (DTCs) constitute the primary histological subtype within thyroid cancer. Due to DTCs’ distinctive radioiodine (RAI) uptake mechanism, standard treatment involving surgery, with or without adjunctive therapy using RAI and levothyroxine inhibition, typically yields favorable prognoses for the majority of patients with DTCs. However, this favorable outcome does not extend to individuals with decreased RAI uptake, termed radioiodine-refractory thyroid cancers (RAI-RTCs). Recent research has revealed that the genetic mutations and gene rearrangements affecting sites such as RTKs, RAS, BRAF and TERTp lead to structural and functional abnormalities in encoded proteins. These abnormalities aberrantly activate signaling pathways like the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-hydroxykinase (PI3K) signaling pathways, resulting in thyroid cells dedifferentiation, sodium/iodide symporter (NIS) dysfunction, and consequent the RAI-refractory nature of DTCs. Targeted therapy tailored to mutations presents a promising avenue for the treatment of RAI-RTCs. Lenvatinib and sorafenib, multi-kinase inhibitors, represent the standard first-line systemic treatment options, while cabozantinib is the standard second-line treatment option, for this purpose. Furthermore, ongoing clinical trials are exploring selective kinase inhibitors, immune checkpoint inhibitors, and combination therapies. Notably, numerous clinical trials have demonstrated that selective kinase inhibitors like BRAF, MEK and mTOR inhibitors can restore RAI uptake in tumor cells. However, further validation through multicenter, large-sample, double-blinded randomized controlled trials are essential. Enhanced treatment strategies and innovative therapies are expected to benefit a broader spectrum of patients as these advancements progress.
Immune checkpoint inhibitors (ICIs) are a new type of antitumor drug which can achieve antitumor goals by blocking the binding of immune checkpoints to their ligands, thereby enhancing the activity of T cells. Meanwhile, ICIs block the binding of immune checkpoints to their ligands, disrupting the immune tolerance of T cells to self-antigens, which may lead to a series of immune-related adverse events (irAEs). Immune checkpoint inhibitor-induced hypophysitis (IH) is a relatively rare irAE. Due to the lack of specificity in clinical manifestations, it is difficult to accurately diagnose IH in a timely manner in clinical practice. However, the risk of adverse events, especially IH, for patients receiving ICIs has not been adequately investigated. Missed or delayed diagnosis may lead to poor prognosis or even adverse clinical outcomes. In this article, we summarize the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of IH.
Purpose: Cardiac magnetic resonance imaging (CMRI) provides a detailed method for understanding the specific cardiovascular alterations associated with acromegaly. This study aimed to evaluate the impact of personalized treatment on cardiac structure, function, and myocardial tissue characteristics using CMRI, and to assess the effects of biochemical remission on improving cardiovascular complications in acromegaly patients.Method: Thirty-nine acromegaly patients were enrolled from July 2020 to February 2023 at West China Hospital of Sichuan University. Comprehensive cardiac assessments were conducted using a 3.0 T MRI scanner at baseline and one year after individualized treatment.Results: Among the 30 patients who completed both baseline and one-year follow-up CMRI examinations, significant reductions in left ventricular (LV) wall thickness and end-diastolic diameter were observed compared to baseline (both P < 0.05). Left ventricular mass (LVM) and mass index (LVMi) also significantly decreased (LVM: 90.17 ± 25.86 g vs. 101.18 ± 26.10 g, P=0.007; LVMi: 50.01 ± 12.56 g/m2vs. 56.20 ± 13.01 g/m², P=0.008). Additionally, T2 values showed a significant reduction following individualized treatment (basal T2: 39.12 ± 2.82 ms vs. 42.91 ± 4.38 ms, P<0.001; apical T2: 41.96 ± 3.87 ms vs. 45.13 ± 4.87 ms, P=0.021). Compared to healthy controls, patients who achieved biochemical remission exhibited increased LV inferior septal thickness and elevated extracellular volume (ECV) values. However, T2 value in the basal layer of the LV was significantly lower in the remission group compared to healthy controls.Conclusion: Patients with acromegaly exhibited LV hypertrophy, enlargement, myocardial fibrosis and impaired systolic function assessed by CMRI compared with healthy controls. Individualized treatment led to partial reversed of these abnormalities, particularly in those who achieved biochemical remission.
1 January 2024 in International Journal of Endocrinology
The majority of acromegaly and gigantism are caused by growth hormone‐secreting pituitary neuroendocrine tumors (PitNETs). Most cases can be cured or controlled by surgery, medical therapy, and/or radiotherapy. However, a few of these tumors are resistant to traditional therapy and always have a poor prognosis. The title aggressive/refractory is used to differentiate them from pituitary carcinomas. To date, there is no definitive conclusion on how to diagnose aggressive/refractory growth hormone‐secreting PitNETs, which may have slowed the process of exploring new therapeutical strategies. We summarized the literature described diagnosis and treatment of the disease. Potential disease markers and prospective therapies were also included.
Background: Posterior pituitary tumors (PPTs) are extremely rare, with fewer than 400 cases reported to date. In 2022, the World Health Organization (WHO) classified four types of tumors originating from the posterior pituitary: traditional pituicytoma, oncocytic pituicytoma, granular pituicytoma, and ependymal pituicytoma. To our knowledge, only one subject with coexistence of Cushing’s disease and oncocytic pituicytoma (spindle cell oncocytoma) has been reported, but the clinical features of this patient were not described in detail.Case presentation: We presented a case of a patient with Cushing’s syndrome and a pituitary mass. Transsphenoidal surgery was performed, and pathologic examination revealed two distinct tumors: a corticotroph adenoma with a diameter of less than 2 mm and a larger oncocytic pituicytoma. Post-surgery serum cortisol was 51 nmol/L, indicating complete remission. Corticotroph adenoma or corticotroph hyperplasia was identified after surgery in less than half of the subjects with Cushing’s disease and PPT.Conclusions: Our study indicates that Cushing’s disease in patients with PPT may be caused by the existence of collision lesions, with corticotroph adenoma or hyperplasia being difficult to detect due to their small dimensions.